NCT05413044 2025-12-08
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
Bristol-Myers Squibb
Completed
Clinical Trials
37 trialsNCT05421442 2025-12-08
DANBIO
Bristol-Myers Squibb
Completed
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT03016013 2024-09-26
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
RemeGen Co., Ltd.
Phase 3 Completed
NCT01242488 2024-07-17
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
UCB Pharma
Phase 2 Completed
NCT04721821 2024-04-12
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Pfizer
Completed
NCT02760433 2023-09-21
CREDO 3
R-Pharm
Phase 3 Completed
NCT00048321 2022-12-05
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
Ionis Pharmaceuticals, Inc.
Phase 2 Completed
NCT03670667 2022-05-18
A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents
Bristol-Myers Squibb
Completed
NCT03449758 2022-04-28
SariPRO
Sanofi
Phase 4 Completed
NCT03663829 2022-03-09
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
Bristol-Myers Squibb
Completed
NCT01960855 2021-08-24
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
AbbVie
Phase 2 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT01764321 2020-12-22
NexT
UCB Pharma
Completed
NCT03348046 2020-03-04
PASSRRA
Hikma Pharmaceuticals LLC
Completed
NCT01721044 2019-09-18
RA-BEACON
Eli Lilly and Company
Phase 3 Completed
NCT00960440 2018-12-19
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Pfizer
Phase 3 Completed
NCT02046603 2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3 Completed
NCT02679001 2018-07-26
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
Hoffmann-La Roche
Completed
NCT00503425 2017-08-15
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
Hoffmann-La Roche
Phase 3 Completed
NCT01362062 2017-08-02
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Hoffmann-La Roche
Completed
NCT00357903 2017-02-09
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Amgen
Phase 3 Completed
NCT01715896 2016-10-31
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
MedImmune LLC
Phase 2 Completed
NCT00468546 2016-10-25
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
Hoffmann-La Roche
Phase 3 Completed
NCT01613027 2016-10-24
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
Hoffmann-La Roche
Completed
NCT01641952 2016-08-17
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
Hoffmann-La Roche
Completed
NCT01309282 2016-08-12
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
Hoffmann-La Roche
Completed
NCT02519387 2016-07-20
Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity
Mundipharma Pharmaceuticals Sdn. Bhd.
Phase 4 Completed
NCT01350804 2016-05-23
NURTURE 1
Novartis
Phase 3 Completed
NCT01069419 2015-10-29
FasT
UCB Pharma
Completed
NCT00883753 2014-08-06
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Hoffmann-La Roche
Phase 3 Completed
NCT00361335 2014-07-29
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Centocor, Inc.
Phase 3 Completed
NCT01463059 2013-03-25
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
UCB Pharma
Phase 2 Completed
NCT01294722 2013-03-19
A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea
Janssen Korea, Ltd., Korea
Completed
NCT00048581 2011-11-21
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Bristol-Myers Squibb
Phase 3 Completed
NCT01078571 2011-10-28
DALI
Abbott
Completed
NCT00035334 2006-02-14
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Bellus Health Inc. - a GSK company
Phase 2/3 Completed